Atlas Venture
SelectiveFiled to raiseCambridge, MABiotech & pharma, Enterprise software, Medical devicesLast fund filed August 2025
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Atlas Venture Opportunity Fund Ill | August 2025 | $400M | $400M | 84 |
| Atlas Venture Fund XIV | December 2024 | $450M | $450M | 84 |
| Atlas Venture Fund XIII | March 2022 | $450M | $450M | 87 |
| Atlas Venture Opportunity Fund II | September 2021 | $300M | $300M | 69 |
| Atlas Venture Fund XII | May 2020 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Jean-Francois FormelaNot on the current fund | Slowing | Biotech & pharma | 17 |
Categories of Atlas Venture’s own portfolio companies, based on 51 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Atlas Venture’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Abingworth Bioventures | 7 | Antares Therapeutics, IFM Cinque, IFM Continua, IFM Quattro, IFM Tre, Scorpion Therapeutics, Triana Biomedicines |
| Omega Funds | 3 | Ikena Oncology, Morphic Holding, Scorpion Therapeutics |
| Bain Capital Life Sciences | 2 | Editas Medicine, Xilio Therapeutics |
| $400M |
| $400M |
| 85 |
| Atlas Venture Opportunity Fund I | December 2018 | $250M | $250M | 47 |
| Atlas Venture Fund XI | June 2017 | $350M | $350M | 70 |
| Atlas Venture Fund XFiled to raise in 2014, with no closing reported yet. | 2014 | $250M | $0 | 0 |
| 1 |
| Michael Gladstone | Slowing | Biotech & pharma | 3 | 1 |
| Bruce Booth | Quiet | Biotech & pharma | 11 | 0 |
| David GrayzelNot on the current fund | Quiet | Biotech & pharma | 7 | 0 |
| Jason Rhodes | Quiet | Biotech & pharma | 3 | 0 |
| Kevin Bitterman | Quiet | Biotech & pharma, Enterprise software, Medical devices | 13 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| Amagma, Direct Vet Marketing |
| Curie Bio | 2 | Editas Medicine, Magenta Therapeutics |
| Hatteras Venture Partners | 2 | Lysosomal Therapeutics, Vigil Neuroscience |
| Third Rock Ventures | 2 | Kala Pharmaceuticals, Triana Biomedicines |
| Venbio Global Strategic | 2 | Akero Therapeutics, Caldera Therapeutics |
| Vida Ventures | 2 | Scorpion Therapeutics, Vigil Neuroscience |
| Bessemer Venture Partners | 1 | On-Q-ity |
| Centana Growth Partners | 1 | Direct Vet Marketing |
| Cofounders Capital | 1 | Xilio Therapeutics |
| HLM Venture Partners | 1 | Direct Vet Marketing |
| Insight | 1 | Direct Vet Marketing |
| Lux Capital | 1 | Kala Pharmaceuticals |
A shared board seat: a company where filings name a Atlas Venture partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.